Member Directory - Pharmaceutical Advisory Board
Primary tabs
Chair: Charles Flexner
Objectives:
- Engage industry in conversations and serve as a key resource to identify barriers in development and to encourage production of LA/ER ARV’s
- Identify additional experts who can make meaningful contributions to LA/ER topic-specific focus groups, including the generation of educational materials and consensus publications.
Charles W. Flexner, MD, is the Principal Investigator of the Long Acting/Extended Release Antiretroviral Resource Program (LEAP). Conflict of Interest: Receives consulting fees from Gilead Sciences, Merck, Janssen, ViiV Healthcare. Has an ownership interest in Navigen LLC, and receives grant funding from Gilead Sciences. |
Daniel E Cohen, MD, is a Group Medical Director in Clinical Development at AbbVie. Conflict of Interest: Dr. Cohen is an employee and stockholder of AbbVie. |
Jay Grobler is Director, Infectious Disease Biology, at Merck Research Laboratories. Conflict of Interest: None disclosed. |
Dr. James F. Rooney joined Gilead Sciences in 1996 as Vice President of Clinical Research and in 2004 became Vice President of Medical Affairs. Conflict of Interest: None disclosed. |
Bill Spreen, Pharm.D, is a Director of Research and Development at ViiV Healthcare and based in Research Triangle Park, North Carolina. Conflict of Interest: None disclosed. |
Kati Vandermeulen, M.SC., is a Senior Director, Compound Development Team Leader at Janssen Infectious Diseases Research and Development in Beerse Belgium. Conflict of Interest: Has no real or apparent conflicts of interest to report. |